Juniper Biomedical in the News
September, 2024
New CMO appointed
Chief Medical Officer joins executive team
We're pleased to welcome Dr. Jessica DeLong, MD, FACS as our new Chief Medical Officer. Dr. Jessica DeLong's surgery internship and urology residency were completed at the Lahey Clinic in Massachusetts. She went on to complete her fellowship in Adult and Pediatric Reconstructive Urology at Eastern Virginia Medical School in 2014. She is an Associate Professor of Urology, specializing in pelvic floor and genitourinary reconstruction. Dr. DeLong has published in several journals and texts as well as presenting extensively both at the national and international level. She consults in the Urology and Urogynecology, helping companies in both biomedical device development.
May, 2024
AUGS features Juniper CEO David Constantine as speaker
CEO discusses role of clinicians in development & commercialization
By invitation of the American Urogynecologic Society (AUGS), Juniper's CEO & Co-Founder David Constantine discussed the various crucial roles clinicians can play in the development and commercialization of high impact innovation during the American Urogynecologic Society's Efficiency and Productivity Session of the Business Side of Medicine Course.
May, 2024
Juniper accepted into MedTech Innovator
Prestigious accelerator selects company as part of 2024 cohort
Juniper was accepted into the 2024 MedTech Innovator (MTI) cohort, the largest accelerator in the world for medical device, digital health and diagnostic companies with a 5% acceptance rate from over 1,400 annual submissions. Based on evaluations at pitch events and subsequent diligence, MTI’s strategic partners such as Asahi Intecc, BD, Dexcom, Edwards Lifesciences, Johnson & Johnson, NIPRO, Olympus, W. L. Gore & Associates, and Zimmer Biomet selected 65 companies to be in this year’s cohort.
May, 2024
Jayme Coates appointed as Chief Operating Officer
Promotion will enable company to scale
Juniper Biomedical announces the promotion of Jayme Coates to the position of Chief Operating Officer (COO). Jayme has been an invaluable member of the team, leading R&D as well as Operations with exceptional dedication and strategic vision. Her leadership has been instrumental in driving innovation of our unique neuromodulation micro-implant. In her new role , Jayme will oversee the company’s efforts in support of commercialization, including clinical trials and further product and technology development.
April, 2024
Selected to present at AUA
Innovation Nexus Showcase Features Juniper Biomedical's development progress
Juniper Biomedical had the honor to present at the American Urological Association's (AUA) Innovation Nexus Showcase where we were able to share some of our progress including, filing an additional 7 patents to our existing portfolio, filing 2 separate FDA Pre-Submissions and accelerating clinical design of our implant prototype.
April, 2024
Juniper Biomedical Secures Funding to Accelerate Growth and Innovation
Juniper announces an oversubscribed $2M Series Seed financing
The company announced an oversubscribed $2M Series Seed financing. The funding round, led by Auroral Holdings, a MedTech focused family office, with participation from Atma Capital, Hub Angels, Beacon Angels and other private investors, will enable Juniper Biomedical to complete numerous development and commercialization milestones for their platform neuromodulation technology.
March, 2024
Juniper LSI USA 2024 Presenter
Company discusses its breakthrough technology
|
We were honored to present at the LSI USA ‘24 Emerging MedTech Summit. Watch the pitch presentation here! Yes, Juniper Biomedical recently presented at the LSI USA '24 Emerging Medtech Summit. David Constantine, CEO & Co-founder, showcased the company's innovative precision neuromodulation micro-implant designed to treat pelvic health conditions, including urinary incontinence. |
February, 2024
Neuromod Prize Winners
Team awarded $1M to further development of unique micro-neuromodulation implant
|
The team was awarded $1M as a winner of the Neuromod Prize, a competition designed to accelerate the development of targeted neuromodulation therapies. The Neuromod Prize is a SPARC (Stimulating Peripheral Activity to Relieve Conditions) initiative from the National Institutes of Health (NIH) Common Fund. The competition seeks groundbreaking uses of peripheral nerve stimulation that can independently regulate two or more desired autonomic functions without unintended effects on non-target organs. |
February, 2024
Juniper Biomedical selected to present at SUFU annual conference
2024 SUFU meeting featured presentation by co-founders
The Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) selected Juniper Biomedical to present at its annual conference, where co-Founders, Mario Romero-Ortega and David Constantine shared some of the team's preclinical urinary incontinence data that supports the effectiveness of a new and transformative targeted neuromodulation therapy.
January, 2024
RBI Medical rebrands to Juniper Biomedical
Company changes branding to better reflect its vision
RBI Medical is now Juniper Biomedical. This new branding helps underscore the company's vision to restore human nature by dramatically improving therapy for patients with pelvic health conditions. The new LinkedIn page for the company is located here.
April, 2023
Company closes initial Series Seed
Funding will accelerate innovation
RBI Medical successfully closes its Series Seed funding round raising a total of $1.17 million. The funding round saw enthusiastic participation from a diverse group of investors, led by Auroral Holdings. The capital raised will be instrumental in accelerating the development of RBI's micro-neuromodulation implant as well as commercialization strategy formulation.
August, 2022
RBI Medical wins Neuromod Prize Phase 1 nod
Nationwide judging panel chooses 8 teams for $100,000 non-dilutive prize
The National Institutes of Health (NIH) announced eight Phase 1 winners of the Neuromod Prize. The competition received 45 submissions from independent teams, small companies, universities, and medical centers. The winning solutions have demonstrated potential to reduce pain, restore function, and address debilitating conditions - improving patient quality of life with limited side effects.
Phase 2 will invite the winning teams to build on their submissions by conducting proof-of-concept studies. The competition will provide additional resources to help teams accelerate and develop their solutions.
December, 2021
Exclusive License from University of Texas
University grants license to pelvic health focused MedTech company
RBI Medical has secures an exclusive patent license from the University of Texas. This agreement grants Juniper Biomedical the rights to develop and commercialize groundbreaking neuromodulation technologies. The licensed technology, which includes several key patents, is poised to revolutionize the field of minimally invasive neuromodulation.
June, 2020
First internally developed working prototype
RBI unveils first working prototype of revolutionary neuromodulation device
RBI Medical, a pioneering leader in neuromodulation technology, proudly announces the successful development of its first working prototype. The prototype is designed to provide precise and minimally invasive neuromodulation therapy, offering hope to millions of patients suffering from pelvic health conditions such as urinary incontinence.
October, 2020
RBI Medical wins UMass / Hologic Award
RBI awarded with Hologic Industry Partner Award
The RBI team is thrilled to receive the Industry Partner Award, presented by Hologic. The prestigious award includes a share of the $200,000 in sponsor-provided, in-kind support from the UMASS Lowell M2D2 Challenge which will enable RBI to further its research and product development efforts. 15 Finalists, chosen from nearly 250 entries, made their pitches. See the winning pitch here.
June, 2020
RBI selected for MassMedic MedTech Ignite Cohort
Young MedTech company selected for 2020 cohort
RBI Medical has been selected as part of the 2020 cohort for the MassMEDIC IGNITE program. This virtual accelerator is designed to support and nurture MedTech startups through training, mentorship, and networking opportunities. The 2020 cohort included 21 ventures from various categories, including women’s health, telehealth, surgical devices, and more. The program aims to help these startups advance their technologies and business strategies.
June, 2020
RBI selected as MassChallenge Finalist
Early-stage neuromodulation company selected as cohort finalist
RBI Medical has been announced as a finalist within the 2020 MassChallenge Boston cohort. MassChallenge is a global network of zero-equity startup accelerators, and being selected as a finalist is a significant achievement. The 2020 cohort includes 100 early-stage startups, rigorously selected by a community of over 500 expert judges.
February, 2020
RBI Medical welcomes Jayme Coates as VP of R&D and Operations
New leader with extensive neuro-modulation development experience joins team
RBI announces Jayme Coates, MS, MBA has joined the company as Vice President of R&D and Operations. Jayme brings extensive experience in both neuromodulation product development and manufacturing. Her expertise will be invaluable as RBI brings long-awaited innovation to the pelvic health space. We are confident that her leadership and vision will drive our mission forward and enhance our capabilities on both technical and operational fronts.
June, 2019
Greg Martin, PhD joins RBI Medical as CTO
Industry veteran to drive differentiated technology platform
RBI announces Greg Martin, PhD has joined as Chief Technology Officer (CTO). Greg brings a wealth of experience in medical technology and innovation, having previously led successful projects in the MedTech sector at companies such as Hologic, Cytyc and Hemedx. His expertise and vision will be instrumental in developing the company's platform technology, securing intellectual property as well as non-dilutive funding sources.
June, 2019
RBI Medical founded
Worcester, Massachusetts company aims to revolutionize pelvic health therapy
RBI Medical was founded by David Constantine and Mario Romero-Ortega, Ph.D. The company's technology modulates distal target nerves locally by stimulating only the target and can be used to modulate innervation to muscles or organs alike, enabling patients to avail less invasive, safer, and more effective therapy for conditions like incontinence, sexual dysfunction, and chronic pain.